IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-32091-9.html
   My bibliography  Save this article

Cancer immune therapy using engineered ‛tail-flipping’ nanoliposomes targeting alternatively activated macrophages

Author

Listed:
  • Praneeth R. Kuninty

    (TechMed Centre, University of Twente)

  • Karin Binnemars-Postma

    (TechMed Centre, University of Twente)

  • Ahmed Jarray

    (University of Twente
    Wageningen University)

  • Kunal P. Pednekar

    (TechMed Centre, University of Twente)

  • Marcel A. Heinrich

    (TechMed Centre, University of Twente)

  • Helen J. Pijffers

    (TechMed Centre, University of Twente)

  • Hetty Hoopen

    (TechMed Centre, University of Twente)

  • Gert Storm

    (TechMed Centre, University of Twente
    Utrecht University
    National University of Singapore)

  • Peter Hoogevest

    (Phospholipid Research Centre)

  • Wouter K. Otter

    (University of Twente)

  • Jai Prakash

    (TechMed Centre, University of Twente)

Abstract

Alternatively-activated, M2-like tumor-associated macrophages (TAM) strongly contribute to tumor growth, invasiveness and metastasis. Technologies to disable the pro-tumorigenic function of these TAMs are of high interest to immunotherapy research. Here we show that by designing engineered nanoliposomes bio-mimicking peroxidated phospholipids that are recognised and internalised by scavenger receptors, TAMs can be targeted. Incorporation of phospholipids possessing a terminal carboxylate group at the sn-2 position into nanoliposome bilayers drives their uptake by M2 macrophages with high specificity. Molecular dynamics simulation of the lipid bilayer predicts flipping of the sn-2 tail towards the aqueous phase, while molecular docking data indicates interaction of the tail with Scavenger Receptor Class B type 1 (SR-B1). In vivo, the engineered nanoliposomes are distributed specifically to M2-like macrophages and, upon delivery of the STAT6 inhibitor (AS1517499), zoledronic acid or muramyl tripeptide, these cells promote reduction of the premetastatic niche and/or tumor growth. Altogether, we demonstrate the efficiency and versatility of our engineered “tail-flipping” nanoliposomes in a pre-clinical model, which paves the way to their development as cancer immunotherapeutics in humans.

Suggested Citation

  • Praneeth R. Kuninty & Karin Binnemars-Postma & Ahmed Jarray & Kunal P. Pednekar & Marcel A. Heinrich & Helen J. Pijffers & Hetty Hoopen & Gert Storm & Peter Hoogevest & Wouter K. Otter & Jai Prakash, 2022. "Cancer immune therapy using engineered ‛tail-flipping’ nanoliposomes targeting alternatively activated macrophages," Nature Communications, Nature, vol. 13(1), pages 1-17, December.
  • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-32091-9
    DOI: 10.1038/s41467-022-32091-9
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-32091-9
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-022-32091-9?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Raffaella Sabatino & Antonella Antonelli & Serafina Battistelli & Reto Schwendener & Mauro Magnani & Luigia Rossi, 2014. "Macrophage Depletion by Free Bisphosphonates and Zoledronate-Loaded Red Blood Cells," PLOS ONE, Public Library of Science, vol. 9(6), pages 1-12, June.
    2. Daniel S. Chen & Ira Mellman, 2017. "Elements of cancer immunity and the cancer–immune set point," Nature, Nature, vol. 541(7637), pages 321-330, January.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Maria Pouyiourou & Bianca N. Kraft & Timothy Wohlfromm & Michael Stahl & Boris Kubuschok & Harald Löffler & Ulrich T. Hacker & Gerdt Hübner & Lena Weiss & Michael Bitzer & Thomas Ernst & Philipp Schüt, 2023. "Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial," Nature Communications, Nature, vol. 14(1), pages 1-21, December.
    2. Aditi Sahu & Kivanc Kose & Lukas Kraehenbuehl & Candice Byers & Aliya Holland & Teguru Tembo & Anthony Santella & Anabel Alfonso & Madison Li & Miguel Cordova & Melissa Gill & Christi Fox & Salvador G, 2022. "In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response," Nature Communications, Nature, vol. 13(1), pages 1-19, December.
    3. Shaoshuai Tang & Yunzhi Wang & Rongkui Luo & Rundong Fang & Yufeng Liu & Hang Xiang & Peng Ran & Yexin Tong & Mingjun Sun & Subei Tan & Wen Huang & Jie Huang & Jiacheng Lv & Ning Xu & Zhenmei Yao & Qi, 2024. "Proteomic characterization identifies clinically relevant subgroups of soft tissue sarcoma," Nature Communications, Nature, vol. 15(1), pages 1-24, December.
    4. Alexandra Gyurdieva & Stefan Zajic & Ya-Fang Chang & E. Andres Houseman & Shan Zhong & Jaegil Kim & Michael Nathenson & Thomas Faitg & Mary Woessner & David C. Turner & Aisha N. Hasan & John Glod & Ro, 2022. "Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma," Nature Communications, Nature, vol. 13(1), pages 1-18, December.
    5. E. H. Puttock & E. J. Tyler & M. Manni & E. Maniati & C. Butterworth & M. Burger Ramos & E. Peerani & P. Hirani & V. Gauthier & Y. Liu & G. Maniscalco & V. Rajeeve & P. Cutillas & C. Trevisan & M. Poz, 2023. "Extracellular matrix educates an immunoregulatory tumor macrophage phenotype found in ovarian cancer metastasis," Nature Communications, Nature, vol. 14(1), pages 1-16, December.
    6. Heng-Jia Liu & Heng Du & Damir Khabibullin & Mahsa Zarei & Kevin Wei & Gordon J. Freeman & David J. Kwiatkowski & Elizabeth P. Henske, 2023. "mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion," Nature Communications, Nature, vol. 14(1), pages 1-22, December.
    7. Feng Xie & Xiaoxue Zhou & Peng Su & Heyu Li & Yifei Tu & Jinjin Du & Chen Pan & Xiang Wei & Min Zheng & Ke Jin & Liyan Miao & Chao Wang & Xuli Meng & Hans Dam & Peter Dijke & Long Zhang & Fangfang Zho, 2022. "Breast cancer cell-derived extracellular vesicles promote CD8+ T cell exhaustion via TGF-β type II receptor signaling," Nature Communications, Nature, vol. 13(1), pages 1-18, December.
    8. Mengxue Zhou & Jiaxin Wang & Jiaxing Pan & Hui Wang & Lujia Huang & Bo Hou & Yi Lai & Fengyang Wang & Qingxiang Guan & Feng Wang & Zhiai Xu & Haijun Yu, 2023. "Nanovesicles loaded with a TGF-β receptor 1 inhibitor overcome immune resistance to potentiate cancer immunotherapy," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
    9. Meriem Messaoudene & Stéphanie Ferreira & Nathalie Saint-Lu & Mayra Ponce & Caroline Truntzer & Romain Boidot & Clément Bescop & Thomas Loppinet & Tanguy Corbel & Céline Féger & Karine Bertrand & Arie, 2024. "The DAV132 colon-targeted adsorbent does not interfere with plasma concentrations of antibiotics but prevents antibiotic-related dysbiosis: a randomized phase I trial in healthy volunteers," Nature Communications, Nature, vol. 15(1), pages 1-19, December.
    10. Charlotte K. Y. Ng & Eva Dazert & Tuyana Boldanova & Mairene Coto-Llerena & Sandro Nuciforo & Caner Ercan & Aleksei Suslov & Marie-Anne Meier & Thomas Bock & Alexander Schmidt & Sylvia Ketterer & Xuey, 2022. "Integrative proteogenomic characterization of hepatocellular carcinoma across etiologies and stages," Nature Communications, Nature, vol. 13(1), pages 1-18, December.
    11. Shunli Fu & Lili Chang & Shujun Liu & Tong Gao & Xiao Sang & Zipeng Zhang & Weiwei Mu & Xiaoqing Liu & Shuang Liang & Han Yang & Huizhen Yang & Qingping Ma & Yongjun Liu & Na Zhang, 2023. "Temperature sensitive liposome based cancer nanomedicine enables tumour lymph node immune microenvironment remodelling," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    12. Zhongwei Xin & Mingjie Lin & Zhixing Hao & Di Chen & Yongyuan Chen & Xiaoke Chen & Xia Xu & Jinfan Li & Dang Wu & Ying Chai & Pin Wu, 2022. "The immune landscape of human thymic epithelial tumors," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    13. Alessandra Castiglioni & Yagai Yang & Katherine Williams & Alvin Gogineni & Ryan S. Lane & Amber W. Wang & Justin A. Shyer & Zhe Zhang & Stephanie Mittman & Alan Gutierrez & Jillian L. Astarita & Minh, 2023. "Combined PD-L1/TGFβ blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors," Nature Communications, Nature, vol. 14(1), pages 1-19, December.
    14. Weicai Huang & Yuming Jiang & Wenjun Xiong & Zepang Sun & Chuanli Chen & Qingyu Yuan & Kangneng Zhou & Zhen Han & Hao Feng & Hao Chen & Xiaokun Liang & Shitong Yu & Yanfeng Hu & Jiang Yu & Yan Chen & , 2022. "Noninvasive imaging of the tumor immune microenvironment correlates with response to immunotherapy in gastric cancer," Nature Communications, Nature, vol. 13(1), pages 1-14, December.
    15. Stefanie Hiltbrunner & Lena Cords & Sabrina Kasser & Sandra N. Freiberger & Susanne Kreutzer & Nora C. Toussaint & Linda Grob & Isabelle Opitz & Michael Messerli & Martin Zoche & Alex Soltermann & Mar, 2023. "Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    16. Neil H. Segal & Ignacio Melero & Victor Moreno & Neeltje Steeghs & Aurelien Marabelle & Kristoffer Rohrberg & Maria E. Rodriguez-Ruiz & Joseph P. Eder & Cathy Eng & Gulam A. Manji & Daniel Waterkamp &, 2024. "CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    17. Xuejiao Liu & Simin Zhao & Keke Wang & Liting Zhou & Ming Jiang & Yunfeng Gao & Ran Yang & Shiwen Yan & Wen Zhang & Bingbing Lu & Feifei Liu & Ran Zhao & Wenting Liu & Zihan Zhang & Kangdong Liu & Xia, 2023. "Spatial transcriptomics analysis of esophageal squamous precancerous lesions and their progression to esophageal cancer," Nature Communications, Nature, vol. 14(1), pages 1-20, December.
    18. Fotis Nikolos & Kazukuni Hayashi & Xen Ping Hoi & Mark Ellie Alonzo & Qianxing Mo & Armine Kasabyan & Hideki Furuya & Jane Trepel & Dolores Vizio & Jlenia Guarnerio & Dan Theodorescu & Charles Rosser , 2022. "Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    19. Jodi M. Carter & Saranya Chumsri & Douglas A. Hinerfeld & Yaohua Ma & Xue Wang & David Zahrieh & David W. Hillman & Kathleen S. Tenner & Jennifer M. Kachergus & Heather Ann Brauer & Sarah E. Warren & , 2023. "Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    20. Lenka Kasikova & Jana Rakova & Michal Hensler & Tereza Lanickova & Jana Tomankova & Josef Pasulka & Jana Drozenova & Katerina Mojzisova & Anna Fialova & Sarka Vosahlikova & Jan Laco & Ales Ryska & Pav, 2024. "Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer," Nature Communications, Nature, vol. 15(1), pages 1-19, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-32091-9. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.